The genomic landscape of chronic lymphocytic leukemia: clinical implications by Quesada Fernández, Víctor et al.
Quesada et al. BMC Medicine 2013, 11:124
http://www.biomedcentral.com/1741-7015/11/124REVIEW Open AccessThe genomic landscape of chronic lymphocytic
leukemia: clinical implications
Víctor Quesada1*, Andrew J Ramsay1, David Rodríguez1, Xose S Puente1, Elías Campo2 and Carlos López-Otín1Abstract
A precise understanding of the genomic and epigenomic features of chronic lymphocytic leukemia (CLL) may
benefit the study of the disease’s staging and treatment. While recent reports have shed some light on these
aspects, several challenges need to be addressed before translating this research into clinical practice. Thus, even
the best candidate driver genes display low mutational rates compared to other tumors. This means that a large
percentage of cases do not display clear tumor-driving point mutations, or show candidate driving point mutations
with no obvious biochemical relationship to the more frequently mutated genes. This genomic landscape probably
reflects either an unknown underlying biochemical mechanism playing a key role in CLL or multiple biochemical
pathways independently driving the development of this tumor. The elucidation of either scenario will have
important consequences on the clinical management of CLL. Herein, we review the recent advances in the
definition of the genomic landscape of CLL and the ongoing research to characterize the underlying biochemical
events that drive this disease.
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Chronic lymphocytic leukemia (CLL) is a clonal neopla-
sia of B-lymphocytes which accumulate mainly in the
blood, bone marrow, lymph nodes and spleen [1,2].
Notably, these B-lymphocytes are differentiated, and can
remain in an arrested state for several years after diagno-
sis. In spite of its high prevalence in Western countries,
and the consequent interest on its biological and clinical
features, the characterization of the genomic events that
drive this disease proved cumbersome to classical mo-
lecular biology approaches. The main success in this re-
gard was the categorization of CLL in two groups,
depending on whether the tumoral B-cells had un-
dergone the somatic hypermutation (SHM) process in
the germinal center (IGHV-mutated) or not (IGHV-
unmutated) [3]. While IGHV-mutated CLL patients fre-
quently show mild clinical features and high overall
survival (OS) and progression-free survival (PFS), IGHV-
unmutated CLL patients suffer an aggressive form of the
disease which may be refractory to treatment [4]. This* Correspondence: quesadavictor@uniovi.es
1Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo -
IUOPA, Oviedo, Spain
Full list of author information is available at the end of the article
© 2013 Quesada et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbroad classification system was improved with the cha-
racterization of additional genomic and transcriptomic
factors, like inactivating mutations in TP53 [5] and ATM
[6] and expression of ZAP70 [7] and CD38 [8]. Despite
the relatively stable karyotype in CLL cells, genomic ab-
errations were also recognized as important determi-
nants of the clinical course of the disease [9]. Among
these variants, a homozygous deletion at 13q14 which
affects two micro-RNA genes (miR15-a and miR16-1)
was suggested as a triggering event of CLL in about 50%
of the patients [10,11]. However, the genomic events that
dictate the initiation and heterogeneous evolution of
CLL remained partially unknown.Genomic alterations in chronic lymphocytic
leukemia
Next-Generation Sequencing (NGS) techniques have of-
fered, for the first time, an essentially complete and un-
biased picture of a genome in a time- and cost-effective
way, thanks to their ability to read millions of DNA frag-
ments in one experiment [12]. This, in turn, allows the
comparison of the genome of tumor cells with the con-
stitutive genome in normal tissues of the same patient.
The variants present in the tumor genome and absental Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and constitute a requisite of cancer development [13].
With different types of input material and sample
processing, these techniques can detect somatic point
mutations and small insertion/deletions (whole-genome,
whole-exome), chromosome rearrangements (whole-
genome), expression and splicing variants (RNA-Seq)
and changes in the epigenome (ChIP-Seq, bisulfite-based
methods) [14,15]. Notably, whole-exome sequencing is a
two-step procedure in which all known coding regions
of the genome are first purified by targeted capture and
then sequenced. Since these regions span less than 5%
of the genome, this procedure retrieves information on
protein-altering mutations for a small fraction of the
cost of whole-genome sequencing.
Most of the somatic variants in cancer are passenger
mutations, acquired randomly during the lifetime of the
original tumor cell before or during malignant trans-
formation, and provide no advantageous survival phe-
notype. By contrast, a few driver mutations contribute
to the transformation process or allow tumor cells to
survive pharmacological treatments [16]. The primary
strategy to find driver mutations in a tumor type is
inter-tumor recurrence. Because of their functional role,
driver mutations are expected to affect a restricted num-
ber of tumor suppressors and oncogenes, and, therefore,
somatic mutations affecting these genes will be found in
multiple patients with the same type of tumor. To faci-
litate this strategy, the International Cancer Genome
Consortium (ICGC) [17] and the Cancer Genome Atlas
(TCGA) (http://cancergenome.nih.gov/) were formed to
sequence the genomes, transcriptomes and epigenomes
of large cohorts of paired tumor and normal samples
from the most prevalent cancer types.
Given its clinical and societal impact and the gaps in
our knowledge of its genomic determinants, CLL was in-
cluded among the 50 tumors prioritized by the ICGC for
large-scale sequencing. The first result of this effort was
the sequencing and analysis of the whole CLL genome
in two IGHV-mutated and two IGHV-unmutated cases
[18]. This work showed for the first time the usefulness
of next-generation sequencing technologies to find novel
genetic drivers of CLL. Thus, the study described about
1,000 somatic variants per patient, with 45 genes af-
fected by protein-altering somatic mutations. Only four
of those genes were found to be expressed and recur-
rently mutated in a validation set of 169 additional sam-
ples. Therefore, these genes, NOTCH1, MYD88, XPO1
and KLHL6, were singled out as drivers of CLL. Only
NOTCH1 had been previously related to CLL and other
lymphoid malignancies [19]. Functional studies showed
that the observed mutation, a recurrent small deletion
of two coding bases, produces a truncated form of
NOTCH1 that accumulates in the cell. A simultaneousstudy and additional subsequent studies have confirmed
these findings, concluding that NOTCH1 somatic muta-
tion is an independent prognostic factor for aggressive
forms of CLL [20-22]. Therefore, this gene provides an
attractive target for pharmacological intervention [23].
In addition to the discovery of recurrent somatic point
mutations, the mutational profile of the IGHV-mutated
samples suggested that a significant fraction of the
somatic variations could be caused by activation of the
error-prone polymerase-η, a hallmark of the normal
SHM process. This observation relates the clinical differ-
ences between the IGHV-mutated and IGHV-unmutated
CLL subtypes to the underlying genomic events.
This study was followed by two simultaneous whole-
exome analyses of larger cohorts of CLL patients, one in
the context of the ICGC [24] and one from the Broad
Institute [25] (Figure 1). In addition to confirming the
recurrent deletion in NOTCH1, both studies uncovered
protein-altering somatic mutations that recurrently tar-
get multiple genes with varying frequencies (Figure 2).
Thus, the gene encoding SF3B1 accumulates somatic
mutations in about 10% of the CLL cases. In spite of its
known role in the housekeeping process of splicing, this
component of the U2 snRNP spliceosome is the target
of antitumor drugs [26,27], which suggests that SF3B1 is
a bona fide target of driving mutations in CLL. More-
over, several reports have uncovered frequent somatic
mutations affecting this gene in myelodysplasia [28,29]
and other malignancies [30], including solid tumors
[31-33]. In virtually all cases, mutations affect the C-
terminal HEAT-repeat domain of SF3B1, and seem to
cluster in a spatial region of its structure, which suggests
that they disrupt the binding of the protein to some co-
factor, which, in turn, might decrease the splicing fidelity
in specific genes [24]. Consistent with this, and with the
essential function of splicing in eukaryotic biology, mu-
tations in SF3B1 do not lead to widespread changes in
the splicing patterns of tumor cells, as assessed with
RNA-Seq [24,32,34,35]. It is worth noting that SF3B1
also plays a role in polycomb-mediated repression of
Hox genes and, therefore, its role in tumor development
might be independent of RNA splicing [36]. Since the
therapeutic targeting of this protein might provide novel
strategies for the treatment of a large number of CLL
patients with a disease resistant to existing drugs [37],
further studies aimed at determining the exact mecha-
nism that connects SF3B1 mutation to tumor develop-
ment are warranted.
As expected, there is a significant overlap between the
genes that are frequently mutated in these whole-exome
studies of CLL, even though some differences exist,
mainly due to the low number of cases and the low fre-
quency of recurrently mutated genes [24,25,38]. The
highest deviation occurs with mutations affecting TP53,
Figure 1 Recurrent mutations in CLL. The size of each gene symbol is proportional to the logarithm of the mutational frequency of the
corresponding gene as described in Quesada et al. (2011) and Wang et al. (2011) ([24,25], respectively). Frequencies have been corrected for gene
size and codon composition as reported in Quesada et al. Genes in red are mutated preferentially in IGHV-unmutated cases, genes in blue are
mutated in IGHV-mutated cases and genes in purple are mutated in both.
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and 15 mutations out of 91 cases in Wang et al.
(Figure 2). This discrepancy is likely due to the lower
risk of CLL progression in the population-based, un-
treated cohort of the first study. In fact, TP53 mutation
is much more frequent in patients who have received
chemotherapy prior to sample extraction. Consistent
with this, TP53 mutation and related alterations have
been associated with disease progression and chemo-Figure 2 Distribution of frequent mutations in CLL. Red boxes indicate
frequently mutated genes in CLL from two whole-exome studies: Quesada
([24,25], respectively). Red boxes also indicate whether the patient was trea
13q14 was detected (13q14_del), and whether the disease was classified asrefractoriness in CLL [39,40]. Nevertheless, these diffe-
rences do not affect the clinical consequences of SF3B1
mutation [41,42].
Epigenomic alterations in chronic lymphocytic
leukemia
Recently, these genomic studies have been complemen-
ted with the first large-scale analysis of the epigenomic
alterations in CLL [43]. In this work, a combination ofwhich patients carry somatic mutations in any of the 50 most
et al. (2011) (case ID in black) and Wang et al. (2011) (case ID in blue)
ted before sample collection (Chemotherapy), whether deletion of
IGHV-unmutated (IGHV-Unmut).
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microarrays was employed to characterize the methylomes
of 139 CLL patients and several B-cell subpopulations.
The results suggest widespread epigenomic reprogram-
ming events during the development of this disease.
Surprisingly, the main feature found in this study was
hypomethylation inside the body of genes, which associ-
ates with the clinical characteristics of each sample. The
inspection of this methylation signature suggests that, in
addition to IGHV-mutated and IGHV-unmutated patients,
there is a third clinical group of CLL patients with in-
termediate phenotypic characteristics. Additionally, the
comparison of the methylation patterns between B-cell
populations led to the conclusion that malignant IGHV-
unmutated B-cells are related to pre-germinal center B
cells, whereas malignant IGHV-mutated B-cells probably
stem from germinal center-experienced B-cells [43]. Fi-
nally, CLL samples with mutations in NOTCH1 and
SF3B1 show a distinct DNA methylation pattern, which
suggests interplay between the most frequent genomic
events and the epigenetic reprogramming associated with
this neoplasia.
The long tail problem in cancer genomics
As one considers less frequently mutated genes in CLL,
the so-called problem of the long tail becomes apparent
[44]. This problem arises when even the highest muta-
tional frequencies in driver genes are low. As a conse-
quence, there is a ‘long tail’ of extremely low-frequency
driver mutations, which hinders the compilation of a
complete catalogue that recapitulates the key genomic
events for every patient. Thus, even when the 50 most
frequently mutated genes are considered, a large number
of patients show no mutation in any of them (Figure 2).
Notably, deletions in 13q14 are more frequent, but this
event by itself has mild clinical consequences [45]. This
long tail problem challenges the search for drivers of
CLL progression and, therefore, the search for novel
guided therapeutic interventions, by statistical analysis
of mutational frequency alone. To overcome this obs-
tacle, several factors may be considered. First, normal
whole-genome and whole-exome experiments are not
sensitive enough to detect sub-clonal populations in
newly-diagnosed patients. Therefore, some driver muta-
tions may be invisible to these techniques until the sub-
clones develop [46,47] or are selected for because of
their resistance to chemotherapy [48]. This feature of
CLL progression may be of paramount importance for
the early prognosis and treatment choice in this disease.
Thus, Landau et al. have shown in a recent manuscript
that the presence of certain somatic mutations even in a
small population of the tumor cells accurately predicts a
high probability of relapse after treatment [49]. In fact,
most of the driver mutations identified previously occurat sub-clonal levels at diagnosis. Only mutations affect-
ing MYD88, chromosome 12 trisomy and del(13q) were
classified as early clonal events. The authors also showed
that clonal evolution is strongly associated with chemo-
therapy, with sub-clones containing mutations in genes
like SF3B1 and TP53 expanding over time [49]. If this
information is known at diagnosis, clinicians may choose
to target those drivers early to prevent relapse, a strategy
which we have called anticipation-based chemotherapy
(ABC) [50].
In addition, low-frequency driver mutations in CLL
may appear at higher frequencies in other malignancies.
For instance, even though mutations affecting BRAF are
infrequent in CLL, they target the same residues as those
in diffuse large B-cell lymphoma, and are clustered with
those found in hairy-cell leukemia [24,51]. Similar rea-
sons suggest that mutations in CCND2 may drive the
development of CLL in a small percentage of cases [18].
These examples illustrate the putative relevance of infre-
quent mutations for the pathogenesis of CLL. An addi-
tional strategy for the characterization of the mutational
landscape of CLL stems from the fact that driver muta-
tions are expected to impact the functional residues of
the encoded gene products. Therefore, after predicting
the functional impact of the somatic variants, infre-
quently mutated genes may be classified as putative dri-
vers if they accumulate more damaging mutations than
expected by chance [52,53]. A similar method groups
mutations that affect a given domain, even if they do not
target the same gene [54].
Finally, algorithms to predict driving mutations may
benefit from biochemical information by grouping to-
gether genes that belong to the same biological path-
ways. Usually, these genes are mutated in a mutually
exclusive way. This approach may yield important clues
about the biochemical determinants of CLL progression,
although the low frequencies involved preclude the
assessment of mutual exclusion in most cases. Neverthe-
less, the alteration of several pathways, including inflam-
matory response, pattern recognition, DNA damage,
RNA splicing and telomere maintenance, has been pos-
tulated as a crucial step in this process [24,25,55]. More-
over, extensive mining of whole-exome and RNA-Seq
data showed that up to one-third of the examined pa-
tients suffer somatic mutations affecting at least one
component of the RNA maturation pathway, including
splicing, exon-junction complex, regulation of alterna-
tive splicing and transport [34]. However, the pattern of
mutations suggests that most of the grouped mutations
are probably passengers of CLL development. The ex-
ception would be RNA transport, in which three genes
(NXF1, XPO1 and DDX3X) are recurrently mutated.
Notably, all of the cases with mutations affecting this
pathway were classified as IGHV-unmutated, which
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velopment of this aggressive form of the disease.
All these factors considered, there is a pressing need
for direct biochemical experiments that confirm and ex-
tend these conclusions. Recent works have tried to re-
capitulate the biological consequences of some of the
described mutations. These studies are highlighting new
pathways in CLL development. For instance, frequent
mutations in POT1, a gene whose product binds telo-
meric DNA and the shelterin complex, seem to affect
telomere maintenance in patient cells [56]. Also, meta-
bolic reprogramming might be involved in this malig-
nant transformation through mutations affecting SI, a
type-II transmembrane enzyme involved in carbohydrate
metabolism [57]. These experiments must be extended
with the development and use of animal models of CLL
to answer some of the most challenging open questions
and investigate new potential pharmaceutical interven-
tions [58-60].
Clinical perspectives
The newly acquired data depicting the genomic land-
scape of CLL have immediately suggested novel and in-
teresting paradigms for the clinical management of this
frequent form of leukemia. For instance, RNA-splicing
inhibitors may provide a previously unsuspected strategy
for the treatment of this neoplasia [61]. Also, somatic
mutations affecting NOTCH1, SF3B1 and TP53 are im-
proving our ability to predict the outcome of the disease
from early stages [45,62]. Several studies have already
been carried out to clinically characterize the conse-
quences of mutations affecting these genes on the prog-
nosis of CLL. Thus, the German CLL Study Group has
sequenced samples from a large cohort of 1,124 newly
diagnosed patients to ascertain the impact of SF3B1 mu-
tations on prognostic markers [63], whereas the CLL8
trial was interrogated for TP53, NOTCH1 and SF3B1
mutations and their relationship with treatment out-
come [64]. These studies have confirmed that SF3B1
mutation correlates with adverse prognostic features,
with independent prognostic value on time to treatment,
and shown that mutations in NOTCH1 and TP53, but
not SF3B1, associate with refractory disease. Import-
antly, a randomized, prospective clinical study in the
context of the British LRF CLL4 trial has independently
demonstrated the prognostic value of NOTCH1 and
SF3B1 mutations, which single out a new group of pa-
tients with poor outcome after treatment with chemo-
therapy [65]. However, given the long tail of infrequent
mutations in CLL, the future of patient care may depend
on our ability to integrate the genomic and epigenomic
data into a few common biochemical pathways. If this
proves feasible, intervention on those pathways may lead
to broad-spectrum treatments which improve OS andPFS for most patients. On the other hand, it seems at
this point that CLL development is driven independently
by changes in multiple, unrelated biological pathways.
This would force us to integrate the genomic informa-
tion into a personalized medicine framework to make
sure that a large percentage of patients receive adequate
care. In this scenario, individual genome sequencing
would become a routine clinical test for precise diag-
nosis, prognosis and targeted therapeutic approaches.
Obviously, this would require solving a wealth of short-
comings, ranging from our limited knowledge of the
influence of mutations on treatment response to the ne-
cessity to take into account sub-clonal events and mi-
croenvironmental interactions which may shape CLL
progression [66,67]. As genome-sequencing, information-
processing and data-storing costs keep decreasing, this
scenario becomes increasingly realistic. Therefore, it
seems likely that information on patient response to treat-
ment in relationship to the genomic events that drive each
CLL case will keep growing to the point where genomic
and epigenomic information will become an important
factor in the clinical management of this disease.
Conclusions
For the first time, we have a comprehensive view of the
genomic landscape of CLL. This provides new bioche-
mical targets for therapeutic intervention and improved
staging procedures. While the resulting model needs to
be experimentally validated, at this point it seems un-
likely that a single strategy can be employed for the
clinical management of a large percentage of patients.
Therefore, it may be necessary to integrate persona-
lized genomic information at diagnosis into the clinical
decision-making process.
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